Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.

ABSTRACT:

Background

The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.

Methods

We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features. For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery prompted oxaliplatin-based o

SUBMITTER: Tie J 

PROVIDER: S-EPMC9701133 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature